Working… Menu
Trial record 1 of 1 for:    VIVID-1 | Crohn Disease
Previous Study | Return to List | Next Study

A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03926130
Recruitment Status : Recruiting
First Posted : April 24, 2019
Last Update Posted : June 9, 2021
Information provided by (Responsible Party):
Eli Lilly and Company

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 23, 2022
Estimated Study Completion Date : April 21, 2023